Literature DB >> 31192749

Model extrapolation to a real-world dataset: evaluation of tacrolimus population pharmacokinetics and drug interaction in pediatric liver transplantation patients.

Dong-Dong Wang1, Xiao Chen1, Meng Fu1, Qing-Shan Zheng2, Hong Xu3, Zhi-Ping Li1.   

Abstract

1. Numerous tacrolimus population pharmacokinetic (PPK) models in pediatric liver transplantation patients have been established to define an optimal dose schedule. However, the applicability of extrapolating these PPK models to our clinical center remains unknown. The goals of the present study was to evaluate model external predictiveness and establish a new model applicable to traditional therapeutic drug monitoring data.2. Published PPK models were collected from the literature and assessed using our real-world dataset including 41 pediatric liver transplantation patients via the individual prediction error method. The establishment of a new model was characterized using non-linear mixed-effects modeling.3. Nine published pediatric liver transplantation PPK models were identified, three of which could be applied to our real-world dataset. However, these models were dissatisfactory in terms of individual prediction error and hence, inadequate for extrapolation. Finally, a new model applicable to our real-world dataset was established as follows: CL/F = 22.9 × (WT/70)0.75 × (1 - WZ × 0.264) × (1 - FCZ × 0.338) × (1 + ASPI × 0.281) × (POD/41)0.0486 L/h; V/F = 906 × (WT/70) L. Where WT, WZ, FCZ, ASPI and POD were weight, Wuzhi capsule, fluconazole, aspirin and post-transplantation day, respectively. In conclusion, published models were inadequate for application to our real-world dataset. The present study produced a new model applicable to our real-world study data.

Entities:  

Keywords:  Model extrapolation; pediatric liver transplantation; population pharmacokinetics; real-world dataset; tacrolimus

Mesh:

Substances:

Year:  2019        PMID: 31192749     DOI: 10.1080/00498254.2019.1631505

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  8 in total

1.  Population pharmacokinetics and pharmacogenomics of tacrolimus in Chinese children receiving a liver transplant: initial dose recommendation.

Authors:  Xiao Chen; Dong-Dong Wang; Hong Xu; Zhi-Ping Li
Journal:  Transl Pediatr       Date:  2020-10

2.  Effects of Posaconazole on Tacrolimus Population Pharmacokinetics and Initial Dose in Children With Crohn's Disease Undergoing Hematopoietic Stem Cell Transplantation.

Authors:  Xiao Chen; Dongdong Wang; Feng Zheng; Lin Zhu; Yidie Huang; Yiqing Zhu; Ying Huang; Hong Xu; Zhiping Li
Journal:  Front Pharmacol       Date:  2022-04-13       Impact factor: 5.988

3.  Population pharmacokinetics of tacrolimus in pediatric patients with systemic-onset juvenile idiopathic arthritis: Initial dosage recommendations.

Authors:  Dongdong Wang; Xiao Chen; Hong Xu; Zhiping Li
Journal:  Exp Ther Med       Date:  2019-10-25       Impact factor: 2.447

4.  Effects of voriconazole on population pharmacokinetics and optimization of the initial dose of tacrolimus in children with chronic granulomatous disease undergoing hematopoietic stem cell transplantation.

Authors:  Xiao Chen; Dongdong Wang; Jianger Lan; Guangfei Wang; Lin Zhu; Xiaoyong Xu; Xiaowen Zhai; Hong Xu; Zhiping Li
Journal:  Ann Transl Med       Date:  2021-09

5.  Population pharmacokinetics and initial dose optimization of tacrolimus in children with severe combined immunodeficiency undergoing hematopoietic stem cell transplantation.

Authors:  Xiao Chen; Dongdong Wang; Feng Zheng; Xiaowen Zhai; Hong Xu; Zhiping Li
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

6.  Initial dose recommendation for sirolimus in paediatric kaposiform haemangioendothelioma patients based on population pharmacokinetics and pharmacogenomics.

Authors:  Xiao Chen; Dong-Dong Wang; Hong Xu; Zhi-Ping Li
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

7.  Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice.

Authors:  Danica Michaličková; Pavel Jansa; Miroslava Bursová; Tomáš Hložek; Radomír Čabala; Jan Miroslav Hartinger; David Ambrož; Michael Aschermann; Jaroslav Lindner; Aleš Linhart; Ondřej Slanař; Elke H J Krekels
Journal:  Pulm Circ       Date:  2020-02-10       Impact factor: 3.017

8.  Initial dosage optimization of ciclosporin in pediatric Chinese patients who underwent bone marrow transplants based on population pharmacokinetics.

Authors:  Xiao Chen; Xin Yu; Dong-Dong Wang; Hong Xu; Zhiping Li
Journal:  Exp Ther Med       Date:  2020-05-08       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.